Newport Beach, California (PRWEB) May 16, 2013
NVISION Laser Eye Centers today announced an agreement with Avellino Labs USA, the developer of the only genetic test for Avellino Corneal Dystrophy (ACD), to be the first in the nation to offer this test; which just became available in the U.S. in March when Avellino Lab USA announced the launch of its Menlo Park, Calif.-based certified molecular diagnostic testing lab.
ACD, a hereditary disease, develops slowly in the eye causing cloudiness at the center of the corneas that could lead to impaired vision or blindness. Carriers of ACD are not candidates for LASIK or PRK, as the treatment may exacerbate the condition.
“We are thrilled to be the first in the nation, and Southern California, to offer this test; which provides an additional level of safety by ruling out patients who should not have LASIK due a hereditary condition such as ACD,” says Todd Cooper, CEO of NVISION Laser Eye Centers.
“Because of this condition, 1 in 870 people are not a candidate for LASIK. The test is so simple to do for it merely requires a cotton swab sample from the inside of your cheek. Within 48 hours, we have the results and can confirm your candidacy for LASIK,” says Dr. Tom Tooma, founder of NVISION Laser Eye Centers. “Avellino testing is one reason that the NVISION Standard of Excellence has made us a leader in eye care since 1999.”
About NVISION Laser Eye Centers
NVISION Laser Eye Centers now has 17 locations throughout California. NVISION Laser Eye Centers is the first provider in California to offer LASIK eye surgery with the Swiss-engineered Ziemer Femto LDVD Crystal Line™ Laser -- the highest level of laser vision correction available today. NVISION is also the first provider in California to offer the bladeless, computer-controlled LenSx laser, unquestionably the most technologically advanced option for laser cataract surgery.
With more than 1,400 eye doctors who refer their patients and trust their own eyes to NVISION surgeons, NVISION Laser Eye Centers is the Eye Doctors’ #1 Choice.
For more information, visit http://www.NVISIONCenters.com or call 1-877-91NVISION (1-877-916-8474).
About Avellino Lab USA
Avellino Lab USA has developed the first and only commercially available testing system for Avellino Corneal Dystrophy (ACD), also known as Granular Corneal Dystrophy type 2. The company’s advanced genetic diagnostics system provides fast, safe and affordable evaluations of an individual’s genetic predisposition to ACD. Known as the Avellino-GENE Detection System (AGDS™) Test, Avellino Lab USA is able to positively identify, with 100 percent accuracy, a patient’s ACD status. Based on the test’s results, patients and their physician can make an informed decision when considering vision correction surgery.